News

Government mulls tightening drug DTC advertising

BY Drew Buono

Drug makers spent $5.4 billion last year on direct-to-consumer advertising, according to the market research firm Nielsen Monitor-Plus. That’s a fivefold increase in the decade since rules about the disclosures required in television ads were changed, allowing drug makers to more easily air commercials. But now, lawmakers are saying that the ads gloss over risks and may cause overprescribing of expensive medicines.

According to Duke University professor Ruth Day, who spoke in front of House Democrats last month at a hearing titled “Direct-to-Consumer Advertising: Marketing, Education or Deception?” about the subject, 80 percent of viewers can recall benefits mentioned in TV drug ads, while only 20 percent successfully recall side effects.

Over the past two months, members of the House have been investigating DTC ads and the impact they have on consumers. Rep. Bart Stupak, D-Mich., head of the Energy and Commerce Subcommittee on Oversight and Investigations, said “Congress needs to decide whether the United States should continue to be one of two countries in the world that allow DTC ads, and if we continue to allow such advertising, whether any further limits to DTC ads should be required. It appears that we need to enforce significant restrictions on DTC ads.”

The American Medical Association, testifying at the hearing, endorsed the proposal that the Food and Drug Administration should review and approve all direct-to-consumer ads for new drugs before they are aired on television. Nancy H. Nielson, president-elect of the AMA, told the House subcommittee that most AMA members don’t like direct-to-consumer advertising of prescription drugs but that they had become a fact of life and may be protected by the First Amendment. The best approach to deal with these ads, Nielson said, would be an FDA review prior to broadcast in order to guarantee that no unwarranted claims were made and that risks and benefits were fairly presented. The AMA said that, “A moratorium should be placed on ads for newly approved drugs until doctors are educated and regulators have signed off on the messages.” Stupak said Congress should consider new restrictions on ads.

In particular, House investigators are focused on four drug makers: Merck and Schering-Plough for marketing of their cholesterol drug Vytorin; Pfizer for using a doctor who does not practice medicine in their ads for their cholesterol drug Lipitor; and the anemia drug Procrit by Johnson & Johnson.

Merck and Schering-Plough were targeted for not releasing the results of their ENHANCE trial, which showed that their cholesterol drug Vytorin did not reduce plaque buildup in arteries compared with one of the ingredients in the drug Zocor alone. The companies, even while withholding the information, continued to aggressively market Vytorin to consumers.

Pfizer senior director James Sage defended his company’s role in using Dr. Robert Jarvik, the physician featured in the company’s Lipitor ad. While Jarvik isn’t a practicing physician, he did help design the first artificial heart.

“Although not a practicing physician, he has devoted his entire career to medical science related to the human heart,” Sage said. “An important objective of the Jarvik advertising campaign for Lipitor was to highlight the importance of diet and exercise in reducing cardiovascular risk.”

Sage, and officials from the other companies, all testified that they submitted the ads to the Food and Drug Administration for comments. Sage noted that Pfizer had made several changes to its ads for Lipitor, including weakening claims about its ability to lower cholesterol compared with other drugs.

Kim Taylor, president of Johnson & Johnson’s Ortho Biotech, which makes Procrit, defended commercials that suggested the drug could relieve fatigue with chemotherapy. Stupak challenged her on this, noting that the drug was approved for chemotherapy-associated anemia, not fatigue per se.

Two weeks after the hearing, Stupak and Rep. John Dingell, DMich., went even further by writing a letter to the chief executives at Merck, Pfizer, Johnson & Johnson and Schering-Plough to voluntarily limit DTC ads for their drugs Vytorin, Lipitor and Procrit, including withholding any ads for new products for two years until certain studies are completed.

“To date, we have not received adequate assurances that the leading pharmaceutical companies share our commitment to providing consumers with accurate information about drug therapies,” Dingell said in a statement.

Included in the letter sent out to the pharmaceutical companies by Stupak and Dingell was a recommendation that the companies add the FDA’s toll-free MedWatch phone number to their advertisements.

Kassy McGourty, spokeswoman for Johnson & Johnson’s OrthoBiotech unit, said the company received the letter and would cooperate with the committee. The other three companies have yet to comment on the letter.

In relation to the last request by Dingell and Stupak, Congress has asked the FDA to study whether adding the toll-free number, which is required in print ads for prescription drugs, would be an effective way to learn about harmful side effects.

This follows a request by Congress made just days before the letters were sent out to the pharmaceutical companies asking the FDA to speed its efforts in forcing drug companies to include safety-reporting information in television and radio ads. FDA spokes-woman Rita Chappelle said the FDA would look at the panel’s recommendations and incorporate them into the design of a study. Once complete, the next step would be to issue regulations and obtain Congressional approval, she said. No quick fix, “It could take some time,” Chappelle said. “It could take a couple of years.”

This news came as a disappointment to some consumer advocate groups that may have been looking for a quicker response. “We want to make sure that this information gets into TV ads sooner, not later,” said Elizabeth Foley, a policy advocate for Consumer Union, who testified before the panel back on May 16. “We want to figure out if there is a way for the FDA to shorten the time it takes to do a study on this proposal.”

Another issue that should be looked at is whether or not consumers understand how to report side effects. While the FDA does have a method for consumers to report a drug’s adverse side effects, most patients, according to a Consumer Reports survey, report side effects to their doctor, while only seven percent report them to the FDA.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

CVS Caremark to expand headquarters, add positions

BY Antoinette Alexander

WOONSOCKET, R.I. CVS Caremark has announced expansion plans for its headquarters over the next two years, a move that will help support the company’s continued growth and current hiring expectations of more than 200 new positions on its corporate campus.

The nature of the new jobs was not disclosed. In Rhode Island, the company currently employs 5,800 associates.

The plans are to build two new 150,000-square-foot office facilities in the Highland Corporate Park in Cumberland, R.I. The company has been based in Highland Corporate Park, which is jointly located in Cumberland and Woonsocket, since 1982. The company significantly expanded its customer support center facilities in 1988 and again in 2000.

“Our company was founded in Rhode Island more than 40 years ago and we feel fortunate to be able to continually reinvest in our home state,” stated Tom Ryan, chairman, president and chief executive officer. “As the largest company in Rhode Island we are looking to further expand our base of operations to support our continued growth and, as a result, increase our workforce over the next few years.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

A&P announces fiscal Q1 improvements

BY Antoinette Alexander

MONTVALE, N.J. A&P, which operates 446 stores under such banners as A&P, Pathmark and Waldbaum’s, announced on Friday improved results for the first quarter as it nears the completion of the Pathmark integration.

“The first quarter of 2008 clearly demonstrates our continuing progression in operating improvement with the achievement of our fourth straight quarter of comparable store sales of over 3 percent,” stated Eric Claus, president and chief executive officer. “Further, Pathmark is already achieving positive results with comparable store sales climbing above 3 percent for the first time in many years. The company is also well underway with the completion of the Pathmark integration, as many of the planned milestones have been achieved. As of the end of the first quarter, our annualized run-rate of synergies is approximately $100 million.”

Sales for the quarter totaled $2.9 billion compared with $1.7 billion in the year-ago period. Same-store sales rose 3.2 percent, which excludes sales for Pathmark stores acquired in December 2007. Same-store sales for Pathmark, measured during the same period, rose 3.1 percent.

Net income from continuing operations was $3.8 million, with a net loss per diluted share of 48 cents after adjusting for non-operating income related to fair value adjustments. This compares with income of $61.4 million, or $1.45 per diluted share, in the year-ago period.

The company did not break out pharmacy sales results.

As previously reported by Drug Store News, the company announced during the quarter an integral step in its transformation—the conversion of the majority of SuperFresh stores in the Philadelphia market to the recently premiered Price Impact format under the Pathmark Sav-A-Center banner and a number of SuperFresh locations retaining the Fresh format with significant upgrades.

Also during the quarter, the supermarket chain completed the remodel of A&P Fresh in Holmdel, N.J., to the updated Fresh format and began remodeling additional stores. The company also premiered its Price Impact format in the Irvington and Edison Pathmark stores.

“The remainder of fiscal 2008 will be focused on progressing the company further toward operating profitability by: moving forward our operating and aggressive merchandising strategies; maintaining cost control and reduction disciplines throughout the business. Integral to our drive to profitability is the continued and ongoing execution of capital improvement projects all geared for maximum return, and particularly weighted to value propositions,” stated Claus.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?